Relma-cel and Tislelizumab for CNS Lymphoma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two drugs for people with large B-cell lymphoma that has spread to the brain or spinal cord and has come back or not responded well to earlier treatments. The first drug, Relma-cel, is a type of immunotherapy that helps your immune system attack cancer cells. The second drug, Tislelizumab, helps keep your immune system active against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have large B-cell lymphoma that has spread to the brain or spinal cord and either came back or didn't respond to at least one prior treatment. Your most recent treatment brought the disease under control (partial or complete response).
- You are generally active and able to take care of yourself (ECOG score 0-2).
- Adequate liver, kidney, and bone marrow function (specific blood test results needed).
- No prior treatment with a CD19-targeted CAR-T cell therapy (like Kymriah or Yescarta).
- No active autoimmune disease requiring treatment in the last year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, for people whose central nervous system lymphoma has come back. The goal is to see if this treatment can help shrink the cancer or slow its growth.
This trial studies camrelizumab (an immune medicine) for primary CNS lymphoma that has come back after standard treatment. It aims to shrink the lymphoma seen on MRI and help control the disease with a new immune-based approach.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
This trial tests a combination of three drugs for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment, or for those who cannot take standard chemotherapy. The goal is to see if this new combination is safe and effective.
This trial tests a new cancer immunotherapy called liso-cel (a CAR T-cell treatment) as a first treatment for people with primary CNS lymphoma who cannot have a stem cell transplant. If you've already received some high-dose methotrexate and your tumor responded, this study may offer a more targeted therapy to try to improve results.
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
Hear when a new CNS Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.